Loading...
Loading...
DOMH| Name | Value |
|---|---|
| Revenues | 6,174.0K |
| Cost of Revenue | 122.0K |
| Gross Profit | 6,052.0K |
| Operating Expense | 8,788.0K |
| Operating I/L | -2,736.0K |
| Other Income/Expense | -3,384.0K |
| Interest Income | 285.0K |
| Pretax | -6,120.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -6,120.0K |
Dominari Holdings Inc. is a biotechnology company specializing in small-molecule anti-cancer therapeutics. Its pipeline includes treatments for prostate cancer, pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is developing DHA-dFdC for pancreatic cancer and KPC34 for acute myeloid leukemia and acute lymphoblastic leukemia. Additionally, it is working on an antiviral platform targeting various viruses, including influenza, Ebolavirus, Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. Dominari Holdings Inc. generates revenue through the development and licensing of these therapeutic and antiviral products.
